NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.349) was uploaded to the NHS England Website on Thursday 20, February 2025.
The following changes have been introduced:
NA (LIS01a)
NA
Recommended for routine commissioning, receiving CDF interim funding
Axicabtagene ciloleucel (AXI01a) ## Axicabtagene ciloleucel (AXI01a)
Axicabtagene ciloleucel for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal cell lymphoma (PMBCL) and transformed lymphoma to DLBCL in patients previously treated with two or more lines of systemic therapy where the following criteria are met: This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (AXI01b) can only be completed as a continuation of this first part of the form (AXI01a) and must be completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of axicabtagene ciloleucel Axicabtagene ciloleucel for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal cell lymphoma (PMBCL) and transformed lymphoma to DLBCL in patients previously treated with two or more lines of systemic therapy where the following criteria are met: This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (AXI01b) can only be completed as a continuation of this first part of the form (AXI01a) and must be completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of axicabtagene ciloleucel
Treatment criterion (#3) updated Treatment criterion (#3) updated
Axicabtagene ciloleucel (AXI01a) ## Axicabtagene ciloleucel (AXI01a)
Axicabtagene ciloleucel for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal cell lymphoma (PMBCL) and transformed lymphoma to DLBCL in patients previously treated with two or more lines of systemic therapy where the following criteria are met: This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (AXI01b) can only be completed as a continuation of this first part of the form (AXI01a) and must be completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of axicabtagene ciloleucel Axicabtagene ciloleucel for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal cell lymphoma (PMBCL) and transformed lymphoma to DLBCL in patients previously treated with two or more lines of systemic therapy where the following criteria are met: This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (AXI01b) can only be completed as a continuation of this first part of the form (AXI01a) and must be completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of axicabtagene ciloleucel
Treatment criterion (#3) updated Treatment criterion (#3) updated
Axicabtagene ciloleucel (AXI02a)
Axicabtagene ciloleucel for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or high grade B-cell lymphoma and either in patients who relapse within 12 months of completion of 1st line chemoimmunotherapy AND who would otherwise be intended for potential stem cell transplantation or who are refractory to 1st line chemoimmunotherapy AND who would otherwise be intended for potential stem cell transplantation where the following criteria are met: This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (AXI02b) can only be completed as a continuation of this first part of the form (AXI02a) and must be completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of axicabtagene ciloleucel
Treatment criterion (#3) updated